← Back to Search

Beta Blocker

Carvedilol for Atrial Fibrillation

N/A
Waitlist Available
Led By Anne M Gillis, M.D.
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will compare the effectiveness of two drugs, carvedilol and metoprolol, in preventing a heart rhythm disorder called atrial fibrillation.

Who is the study for?
This trial is for people with a heart rhythm disorder called paroxysmal atrial fibrillation, who've had symptoms recently. They must be able to consent and not have other serious heart conditions or life-threatening illnesses. It's not for those who can't take beta blockers due to past bad reactions.Check my eligibility
What is being tested?
The study compares two drugs, Carvedilol and Metoprolol, to see which one is better at preventing episodes of irregular heartbeat in patients with atrial fibrillation. Participants will be randomly assigned to receive one of the two medications.See study design
What are the potential side effects?
Possible side effects from both Carvedilol and Metoprolol include dizziness, fatigue, low blood pressure, slow heartbeat, and digestive issues. Each person may experience these differently.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Event-free survival to first detected AF after the one month blanking period for dose titration
Secondary outcome measures
AF Severity Scale
Adverse effects of assigned therapy
CCS AF Symptom Score
+4 more

Trial Design

2Treatment groups
Active Control
Group I: MetoprololActive Control1 Intervention
The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.
Group II: CarvedilolActive Control1 Intervention
The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
780 Previous Clinical Trials
841,434 Total Patients Enrolled
11 Trials studying Atrial Fibrillation
2,166 Patients Enrolled for Atrial Fibrillation
Libin Cardiovascular Institute of AlbertaOTHER
3 Previous Clinical Trials
348 Total Patients Enrolled
Heart and Stroke Foundation of CanadaOTHER
122 Previous Clinical Trials
71,909 Total Patients Enrolled
7 Trials studying Atrial Fibrillation
5,439 Patients Enrolled for Atrial Fibrillation

Media Library

Carvedilol (Beta Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT01608893 — N/A
Atrial Fibrillation Research Study Groups: Metoprolol, Carvedilol
Atrial Fibrillation Clinical Trial 2023: Carvedilol Highlights & Side Effects. Trial Name: NCT01608893 — N/A
Carvedilol (Beta Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01608893 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are elderly individuals, over 80 years of age, qualified to participate in this clinical trial?

"This research is open to individuals over the age of legal consent and younger than ninety years old."

Answered by AI

How many participants have enrolled in this research endeavor?

"Unfortunately, this research project has ceased to enroll participants. It was first published on May 1st 2012 and last edited on the 26th of May 2022. If you are seeking other studies, there are currently 477 clinical trials aiming to recruit patients with atrial fibrillation, as well as 41 Carvedilol-focused medical investigations actively recruiting."

Answered by AI

Which ailments is Carvedilol regularly prescribed to address?

"Carvedilol is primarily used to treat heart failure, but it can also show efficacy in treating conditions like myocardial infarction, chronic stable angina pectoris, and hypesthesia."

Answered by AI

Are there any vacancies still available to participate in this research project?

"At the present moment, this particular medical study is not accepting patient applications. The trial was first announced on May 1st 2012 and last updated on May 26th 2022. If you are searching for alternative trials to participate in, there are 477 studies looking for atrial fibrillation patients and 41 trials seeking people trialing Carvedilol."

Answered by AI

To whom is this clinical investigation open for enrollment?

"This medical trial is looking to enrol 300 people aged 18-90 with atrial fibrillation. In addition, participants must be in sinus rhythm when they begin the study."

Answered by AI

Have any further investigations been performed utilizing Carvedilol?

"Currently, 41 ongoing clinical trials are exploring the efficacy of Carvedilol with 9 being in Phase 3. Multiple sites have been set up across the country, Orlando included, and over nine hundred eighty seven locations are running studies related to this medication."

Answered by AI
~27 spots leftby Jun 2025